BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32348192)

  • 1. Early drop of circulating T cells negatively correlates with the protective immune response to Yellow Fever vaccination.
    Bovay A; Speiser DE; Fuertes Marraco SA
    Hum Vaccin Immunother; 2020 Dec; 16(12):3103-3110. PubMed ID: 32348192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
    Muyanja E; Ssemaganda A; Ngauv P; Cubas R; Perrin H; Srinivasan D; Canderan G; Lawson B; Kopycinski J; Graham AS; Rowe DK; Smith MJ; Isern S; Michael S; Silvestri G; Vanderford TH; Castro E; Pantaleo G; Singer J; Gillmour J; Kiwanuka N; Nanvubya A; Schmidt C; Birungi J; Cox J; Haddad EK; Kaleebu P; Fast P; Sekaly RP; Trautmann L; Gaucher D
    J Clin Invest; 2014 Jul; 124(7):3147-58. PubMed ID: 24911151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses.
    Neves PC; Santos JR; Tubarão LN; Bonaldo MC; Galler R
    PLoS One; 2013; 8(12):e81953. PubMed ID: 24324734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8+ T cells complement antibodies in protecting against yellow fever virus.
    Bassi MR; Kongsgaard M; Steffensen MA; Fenger C; Rasmussen M; Skjødt K; Finsen B; Stryhn A; Buus S; Christensen JP; Thomsen AR
    J Immunol; 2015 Feb; 194(3):1141-53. PubMed ID: 25539816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
    Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination.
    Kongsgaard M; Bassi MR; Rasmussen M; Skjødt K; Thybo S; Gabriel M; Hansen MB; Christensen JP; Thomsen AR; Buus S; Stryhn A
    Sci Rep; 2017 Apr; 7(1):662. PubMed ID: 28386132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.
    Mantel N; Piras-Douce F; Chautard E; Marcos-Lopez E; Bodinham CL; Cosma A; Courtois V; Dhooge N; Gautheron S; Kaufmann SHE; Pizzoferro K; Lewis DJM; Martinon F; Pagnon A; Raynal F; Dereuddre-Bosquet N; Le Grand R
    J Virol; 2024 May; 98(5):e0151623. PubMed ID: 38567951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.
    Sandberg JT; Ols S; Löfling M; Varnaitė R; Lindgren G; Nilsson O; Rombo L; Kalén M; Loré K; Blom K; Ljunggren HG
    J Immunol; 2021 Aug; 207(4):1033-1043. PubMed ID: 34321231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.
    Wieten RW; Goorhuis A; Jonker EFF; de Bree GJ; de Visser AW; van Genderen PJJ; Remmerswaal EBM; Ten Berge IJM; Visser LG; Grobusch MP; van Leeuwen EMM
    J Infect; 2016 Jun; 72(6):713-722. PubMed ID: 27017899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization.
    Co MD; Kilpatrick ED; Rothman AL
    Immunology; 2009 Sep; 128(1 Suppl):e718-27. PubMed ID: 19740333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.
    Campi-Azevedo AC; de Araújo-Porto LP; Luiza-Silva M; Batista MA; Martins MA; Sathler-Avelar R; da Silveira-Lemos D; Camacho LA; de Menezes Martins R; de Lourdes de Sousa Maia M; Farias RH; da Silva Freire M; Galler R; Homma A; Ribeiro JG; Lemos JA; Auxiliadora-Martins M; Caldas IR; Elói-Santos SM; Teixeira-Carvalho A; Martins-Filho OA
    PLoS One; 2012; 7(12):e49828. PubMed ID: 23251351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
    Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
    Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
    Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The early cellular signatures of protective immunity induced by live viral vaccination.
    Kohler S; Bethke N; Böthe M; Sommerick S; Frentsch M; Romagnani C; Niedrig M; Thiel A
    Eur J Immunol; 2012 Sep; 42(9):2363-73. PubMed ID: 22733156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A DNA vaccine against yellow fever virus: development and evaluation.
    Maciel M; Cruz Fda S; Cordeiro MT; da Motta MA; Cassemiro KM; Maia Rde C; de Figueiredo RC; Galler R; Freire Mda S; August JT; Marques ET; Dhalia R
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003693. PubMed ID: 25875109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
    Campi-Azevedo AC; Reis LR; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Antonelli LR; Fonseca CT; Costa-Pereira C; Souza-Fagundes EM; da Costa-Rocha IA; Mambrini JVM; Lemos JAC; Ribeiro JGL; Caldas IR; Camacho LAB; Maia MLS; de Noronha TG; de Lima SMB; Simões M; Freire MDS; Martins RM; Homma A; Tauil PL; Vasconcelos PFC; Romano APM; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA
    Front Immunol; 2019; 10():2192. PubMed ID: 31616412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein structure shapes immunodominance in the CD4 T cell response to yellow fever vaccination.
    Koblischke M; Mackroth MS; Schwaiger J; Fae I; Fischer G; Stiasny K; Heinz FX; Aberle JH
    Sci Rep; 2017 Aug; 7(1):8907. PubMed ID: 28827760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice.
    Ma J; Boudewijns R; Sanchez-Felipe L; Mishra N; Vercruysse T; Buh Kum D; Thibaut HJ; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2021 Dec; 10(1):2279-2290. PubMed ID: 34792431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection.
    Reinhardt B; Jaspert R; Niedrig M; Kostner C; L'age-Stehr J
    J Med Virol; 1998 Oct; 56(2):159-67. PubMed ID: 9746073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.